 Judith Regensteiner
Concepts (531)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intermittent Claudication | 46 | 2022 | 118 | 5.210 |
Why?
| | Diabetes Mellitus, Type 2 | 54 | 2024 | 2433 | 4.660 |
Why?
| | Sex Characteristics | 18 | 2024 | 732 | 3.550 |
Why?
| | Peripheral Arterial Disease | 24 | 2022 | 457 | 3.420 |
Why?
| | Exercise | 47 | 2024 | 1922 | 3.400 |
Why?
| | Exercise Therapy | 31 | 2022 | 412 | 3.060 |
Why?
| | Peripheral Vascular Diseases | 25 | 2011 | 102 | 2.610 |
Why?
| | Sex Factors | 20 | 2024 | 1961 | 2.360 |
Why?
| | Oxygen Consumption | 33 | 2021 | 672 | 2.180 |
Why?
| | Cardiovascular Diseases | 23 | 2024 | 2001 | 2.050 |
Why?
| | Walking | 23 | 2022 | 501 | 2.000 |
Why?
| | Diabetes Mellitus | 18 | 2024 | 997 | 1.970 |
Why?
| | Women's Health | 10 | 2024 | 365 | 1.810 |
Why?
| | Biomedical Research | 8 | 2024 | 637 | 1.540 |
Why?
| | Exercise Test | 38 | 2019 | 613 | 1.450 |
Why?
| | Cardiology | 6 | 2023 | 261 | 1.240 |
Why?
| | Exercise Tolerance | 15 | 2024 | 273 | 1.200 |
Why?
| | American Heart Association | 10 | 2019 | 296 | 1.170 |
Why?
| | Quality of Life | 18 | 2019 | 2693 | 1.140 |
Why?
| | Research Personnel | 5 | 2024 | 156 | 1.080 |
Why?
| | Leg | 13 | 2021 | 237 | 1.060 |
Why?
| | Humans | 184 | 2024 | 129219 | 0.980 |
Why?
| | Mentoring | 3 | 2022 | 130 | 0.920 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2024 | 74 | 0.900 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 204 | 0.860 |
Why?
| | Diabetic Angiopathies | 6 | 2017 | 261 | 0.850 |
Why?
| | Vascular Stiffness | 3 | 2023 | 467 | 0.850 |
Why?
| | Female | 106 | 2024 | 68607 | 0.840 |
Why?
| | Muscle, Skeletal | 14 | 2024 | 1614 | 0.820 |
Why?
| | Male | 101 | 2024 | 63498 | 0.820 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2024 | 428 | 0.800 |
Why?
| | Community Health Services | 2 | 2015 | 227 | 0.790 |
Why?
| | Cardiovascular System | 5 | 2023 | 137 | 0.780 |
Why?
| | Diabetic Cardiomyopathies | 3 | 2016 | 34 | 0.770 |
Why?
| | Education, Medical | 3 | 2020 | 243 | 0.770 |
Why?
| | Periodicals as Topic | 1 | 2024 | 204 | 0.760 |
Why?
| | Insulin Resistance | 12 | 2024 | 1164 | 0.720 |
Why?
| | Lower Extremity | 9 | 2019 | 403 | 0.700 |
Why?
| | Arterial Occlusive Diseases | 7 | 2015 | 80 | 0.680 |
Why?
| | Interdisciplinary Research | 1 | 2020 | 26 | 0.670 |
Why?
| | Aged | 57 | 2024 | 22030 | 0.670 |
Why?
| | Middle Aged | 73 | 2024 | 31075 | 0.660 |
Why?
| | Cardiorespiratory Fitness | 2 | 2019 | 48 | 0.650 |
Why?
| | Endothelium, Vascular | 6 | 2021 | 898 | 0.640 |
Why?
| | Obesity | 19 | 2023 | 2876 | 0.640 |
Why?
| | Sitagliptin Phosphate | 1 | 2019 | 31 | 0.630 |
Why?
| | Diastole | 1 | 2019 | 148 | 0.620 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 45 | 0.610 |
Why?
| | Surveys and Questionnaires | 23 | 2018 | 5394 | 0.610 |
Why?
| | United States | 37 | 2024 | 13873 | 0.600 |
Why?
| | Gender Identity | 1 | 2019 | 121 | 0.580 |
Why?
| | Hypoglycemic Agents | 9 | 2021 | 1218 | 0.580 |
Why?
| | Physical Fitness | 9 | 2016 | 203 | 0.580 |
Why?
| | Metabolomics | 2 | 2020 | 652 | 0.560 |
Why?
| | Brachial Artery | 6 | 2015 | 192 | 0.560 |
Why?
| | Health Status | 4 | 2020 | 755 | 0.550 |
Why?
| | Mitochondria, Muscle | 4 | 2024 | 111 | 0.550 |
Why?
| | Hypertension | 6 | 2022 | 1240 | 0.540 |
Why?
| | Physical Exertion | 7 | 2009 | 205 | 0.540 |
Why?
| | Blood Pressure | 12 | 2021 | 1727 | 0.530 |
Why?
| | Venoms | 1 | 2016 | 29 | 0.530 |
Why?
| | Curriculum | 2 | 2020 | 918 | 0.530 |
Why?
| | Vasodilator Agents | 4 | 2010 | 326 | 0.520 |
Why?
| | Biomarkers | 6 | 2024 | 3968 | 0.500 |
Why?
| | Research Design | 5 | 2024 | 1038 | 0.470 |
Why?
| | Cardiac Rehabilitation | 3 | 2019 | 34 | 0.470 |
Why?
| | Life Style | 9 | 2018 | 460 | 0.460 |
Why?
| | Sleep | 1 | 2020 | 682 | 0.450 |
Why?
| | National Institutes of Health (U.S.) | 4 | 2023 | 122 | 0.450 |
Why?
| | Arteriosclerosis | 5 | 2002 | 88 | 0.440 |
Why?
| | Physicians | 5 | 2024 | 864 | 0.430 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2016 | 383 | 0.420 |
Why?
| | Faculty, Medical | 6 | 2024 | 263 | 0.420 |
Why?
| | Home Care Services | 4 | 2019 | 244 | 0.410 |
Why?
| | Risk Factors | 29 | 2022 | 9747 | 0.410 |
Why?
| | Diabetes Mellitus, Type 1 | 9 | 2024 | 3627 | 0.410 |
Why?
| | Microcirculation | 4 | 2017 | 145 | 0.400 |
Why?
| | Mentors | 4 | 2022 | 178 | 0.390 |
Why?
| | Advisory Committees | 5 | 2019 | 216 | 0.390 |
Why?
| | Longevity | 3 | 2024 | 150 | 0.390 |
Why?
| | Blood Flow Velocity | 4 | 2009 | 404 | 0.380 |
Why?
| | Adult | 40 | 2024 | 35471 | 0.360 |
Why?
| | Peptides | 1 | 2016 | 924 | 0.360 |
Why?
| | Weight Loss | 6 | 2016 | 730 | 0.350 |
Why?
| | Treatment Outcome | 24 | 2022 | 10189 | 0.350 |
Why?
| | Disability Evaluation | 2 | 2011 | 283 | 0.350 |
Why?
| | Ankle | 3 | 2008 | 62 | 0.340 |
Why?
| | Gait | 2 | 2006 | 280 | 0.330 |
Why?
| | Regional Blood Flow | 11 | 2020 | 461 | 0.320 |
Why?
| | Tetrazoles | 3 | 2006 | 38 | 0.320 |
Why?
| | Cardiac Output, Low | 1 | 2009 | 66 | 0.310 |
Why?
| | Physical Endurance | 3 | 2011 | 262 | 0.310 |
Why?
| | Double-Blind Method | 8 | 2019 | 1871 | 0.300 |
Why?
| | Thiazolidinediones | 3 | 2010 | 137 | 0.300 |
Why?
| | Oxygen | 4 | 2018 | 911 | 0.300 |
Why?
| | Research Support as Topic | 2 | 2020 | 111 | 0.300 |
Why?
| | Recovery of Function | 9 | 2019 | 640 | 0.300 |
Why?
| | Cost of Illness | 3 | 2018 | 278 | 0.300 |
Why?
| | Fear | 1 | 2011 | 348 | 0.290 |
Why?
| | Oxidative Phosphorylation | 2 | 2019 | 187 | 0.280 |
Why?
| | Follow-Up Studies | 9 | 2024 | 4886 | 0.280 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2020 | 112 | 0.280 |
Why?
| | Hematologic Agents | 1 | 2006 | 1 | 0.270 |
Why?
| | Activities of Daily Living | 5 | 2021 | 383 | 0.270 |
Why?
| | Blood Glucose | 10 | 2024 | 2094 | 0.270 |
Why?
| | Perception | 1 | 2009 | 337 | 0.270 |
Why?
| | Caregivers | 3 | 2024 | 813 | 0.270 |
Why?
| | Medicare | 2 | 2022 | 719 | 0.260 |
Why?
| | Stents | 6 | 2015 | 504 | 0.260 |
Why?
| | Disease Management | 4 | 2017 | 586 | 0.250 |
Why?
| | Motor Activity | 5 | 2012 | 676 | 0.250 |
Why?
| | Foundations | 2 | 2018 | 24 | 0.240 |
Why?
| | Vascular Diseases | 4 | 2000 | 241 | 0.240 |
Why?
| | Feasibility Studies | 2 | 2022 | 864 | 0.240 |
Why?
| | Vascular Surgical Procedures | 5 | 2009 | 294 | 0.240 |
Why?
| | Societies, Medical | 3 | 2017 | 747 | 0.240 |
Why?
| | Pharmacovigilance | 1 | 2024 | 21 | 0.240 |
Why?
| | Interdisciplinary Studies | 2 | 2017 | 28 | 0.230 |
Why?
| | Echocardiography | 4 | 2018 | 626 | 0.230 |
Why?
| | Troponin | 1 | 2024 | 50 | 0.230 |
Why?
| | Vasodilation | 3 | 2015 | 473 | 0.230 |
Why?
| | Troponin T | 1 | 2024 | 57 | 0.230 |
Why?
| | Respiration | 3 | 1990 | 191 | 0.220 |
Why?
| | Insulin | 5 | 2020 | 2324 | 0.220 |
Why?
| | Fibrinolysis | 2 | 2003 | 137 | 0.220 |
Why?
| | Troponin I | 1 | 2024 | 75 | 0.220 |
Why?
| | Heart Rate | 6 | 2015 | 800 | 0.220 |
Why?
| | Overweight | 6 | 2023 | 529 | 0.220 |
Why?
| | Chest Pain | 1 | 2024 | 89 | 0.210 |
Why?
| | Medroxyprogesterone | 4 | 1991 | 10 | 0.210 |
Why?
| | Kinetics | 5 | 2015 | 1641 | 0.210 |
Why?
| | Pulse Wave Analysis | 3 | 2023 | 248 | 0.210 |
Why?
| | Lung Diseases | 3 | 2019 | 741 | 0.210 |
Why?
| | Muscles | 7 | 1994 | 322 | 0.210 |
Why?
| | Minority Groups | 2 | 2022 | 249 | 0.210 |
Why?
| | Iliac Artery | 2 | 2014 | 56 | 0.210 |
Why?
| | Polyhydroxyethyl Methacrylate | 1 | 2002 | 10 | 0.210 |
Why?
| | Financing, Organized | 2 | 2020 | 30 | 0.210 |
Why?
| | Financial Management | 1 | 2022 | 15 | 0.200 |
Why?
| | Predictive Value of Tests | 5 | 2017 | 1944 | 0.200 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2002 | 89 | 0.200 |
Why?
| | Vitamin E | 1 | 2003 | 120 | 0.200 |
Why?
| | Glucose Intolerance | 1 | 2024 | 142 | 0.200 |
Why?
| | Practice Guidelines as Topic | 4 | 2019 | 1493 | 0.200 |
Why?
| | Orthopedics | 1 | 2024 | 135 | 0.200 |
Why?
| | Ascorbic Acid | 1 | 2003 | 120 | 0.190 |
Why?
| | Endovascular Procedures | 2 | 2018 | 301 | 0.190 |
Why?
| | Estrogens, Conjugated (USP) | 3 | 1991 | 46 | 0.190 |
Why?
| | Academic Medical Centers | 3 | 2020 | 480 | 0.190 |
Why?
| | Congresses as Topic | 2 | 2020 | 214 | 0.180 |
Why?
| | Qualitative Research | 3 | 2024 | 1227 | 0.180 |
Why?
| | Organizational Innovation | 2 | 2020 | 138 | 0.180 |
Why?
| | Placebos | 3 | 2019 | 201 | 0.180 |
Why?
| | Arginine | 1 | 2003 | 264 | 0.180 |
Why?
| | Adiponectin | 2 | 2016 | 234 | 0.180 |
Why?
| | Interdisciplinary Communication | 2 | 2020 | 186 | 0.180 |
Why?
| | Severity of Illness Index | 4 | 2009 | 2736 | 0.180 |
Why?
| | Sulfonylurea Compounds | 2 | 2019 | 46 | 0.180 |
Why?
| | Echocardiography, Doppler | 3 | 2016 | 108 | 0.180 |
Why?
| | Sex Distribution | 2 | 2020 | 359 | 0.170 |
Why?
| | Precision Medicine | 2 | 2024 | 387 | 0.170 |
Why?
| | Neovascularization, Physiologic | 2 | 2012 | 176 | 0.170 |
Why?
| | Patient Compliance | 4 | 2015 | 564 | 0.170 |
Why?
| | Time Factors | 11 | 2018 | 6549 | 0.170 |
Why?
| | Cardiovascular Agents | 2 | 2014 | 156 | 0.170 |
Why?
| | Hemodynamics | 6 | 2009 | 1086 | 0.160 |
Why?
| | Clinical Trials as Topic | 6 | 2019 | 1004 | 0.160 |
Why?
| | Arteries | 3 | 2016 | 263 | 0.160 |
Why?
| | Forearm | 2 | 2015 | 117 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2006 | 1360 | 0.160 |
Why?
| | Case-Control Studies | 7 | 2024 | 3372 | 0.160 |
Why?
| | Pediatric Obesity | 2 | 2017 | 570 | 0.160 |
Why?
| | Body Composition | 5 | 2014 | 649 | 0.160 |
Why?
| | Body Mass Index | 9 | 2017 | 2267 | 0.150 |
Why?
| | Telerehabilitation | 1 | 2019 | 36 | 0.150 |
Why?
| | Adolescent | 12 | 2022 | 20378 | 0.150 |
Why?
| | Cross-Sectional Studies | 8 | 2014 | 5057 | 0.150 |
Why?
| | Cause of Death | 1 | 2020 | 392 | 0.150 |
Why?
| | Burnout, Professional | 1 | 2024 | 407 | 0.150 |
Why?
| | Leadership | 2 | 2020 | 354 | 0.150 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2024 | 538 | 0.150 |
Why?
| | Women's Rights | 1 | 2017 | 4 | 0.150 |
Why?
| | Diabetes Complications | 4 | 2010 | 223 | 0.140 |
Why?
| | Aged, 80 and over | 9 | 2012 | 7061 | 0.140 |
Why?
| | Pentoxifylline | 3 | 2006 | 24 | 0.140 |
Why?
| | Circadian Rhythm | 2 | 2020 | 412 | 0.140 |
Why?
| | Interviews as Topic | 4 | 2024 | 724 | 0.140 |
Why?
| | Resistance Training | 1 | 2020 | 151 | 0.140 |
Why?
| | Health Status Indicators | 4 | 2015 | 167 | 0.140 |
Why?
| | Sexism | 1 | 2018 | 55 | 0.140 |
Why?
| | Program Development | 1 | 2019 | 356 | 0.140 |
Why?
| | Death, Sudden, Cardiac | 1 | 2018 | 179 | 0.140 |
Why?
| | Heart Diseases | 2 | 2019 | 350 | 0.140 |
Why?
| | Colorado | 9 | 2017 | 4412 | 0.130 |
Why?
| | Capillaries | 3 | 2012 | 100 | 0.130 |
Why?
| | Ankle Brachial Index | 2 | 2014 | 36 | 0.130 |
Why?
| | Microvessels | 1 | 2017 | 83 | 0.130 |
Why?
| | Faculty | 1 | 2017 | 136 | 0.120 |
Why?
| | Glucose Tolerance Test | 4 | 2024 | 356 | 0.120 |
Why?
| | Leptin | 1 | 2017 | 218 | 0.120 |
Why?
| | Reference Values | 4 | 2007 | 793 | 0.120 |
Why?
| | Ischemia | 1 | 2019 | 406 | 0.120 |
Why?
| | Blood Vessels | 1 | 2017 | 187 | 0.120 |
Why?
| | Needs Assessment | 1 | 2018 | 360 | 0.120 |
Why?
| | Plethysmography | 3 | 2011 | 107 | 0.120 |
Why?
| | Health Status Disparities | 1 | 2018 | 254 | 0.120 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 68 | 0.120 |
Why?
| | Adiposity | 2 | 2017 | 504 | 0.120 |
Why?
| | Program Evaluation | 2 | 2020 | 873 | 0.120 |
Why?
| | Myocardium | 1 | 2020 | 976 | 0.120 |
Why?
| | Pilot Projects | 2 | 2015 | 1584 | 0.120 |
Why?
| | Ventricular Function | 1 | 2015 | 61 | 0.120 |
Why?
| | Cardiac Output | 1 | 2015 | 156 | 0.120 |
Why?
| | Physical Education and Training | 1 | 1994 | 75 | 0.110 |
Why?
| | Arterial Pressure | 1 | 2015 | 117 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2021 | 1268 | 0.110 |
Why?
| | Endothelium | 1 | 2015 | 120 | 0.110 |
Why?
| | Patient Selection | 4 | 2019 | 662 | 0.110 |
Why?
| | Healthy Volunteers | 1 | 2015 | 199 | 0.110 |
Why?
| | Peripheral Nervous System Diseases | 1 | 1995 | 125 | 0.110 |
Why?
| | Health Care Costs | 2 | 2014 | 367 | 0.110 |
Why?
| | Hyperlipidemias | 3 | 2004 | 126 | 0.110 |
Why?
| | Hypoxia | 3 | 1990 | 1079 | 0.110 |
Why?
| | Diagnostic Self Evaluation | 1 | 2013 | 22 | 0.110 |
Why?
| | Menopause | 3 | 1991 | 297 | 0.100 |
Why?
| | Angioplasty | 2 | 2009 | 47 | 0.100 |
Why?
| | Aortic Diseases | 1 | 2014 | 115 | 0.100 |
Why?
| | Reaction Time | 1 | 2015 | 408 | 0.100 |
Why?
| | Diet, Reducing | 1 | 2013 | 87 | 0.100 |
Why?
| | Carnitine | 5 | 2001 | 76 | 0.100 |
Why?
| | Ventricular Function, Left | 1 | 2016 | 526 | 0.100 |
Why?
| | Students, Medical | 1 | 2017 | 315 | 0.100 |
Why?
| | Retrospective Studies | 4 | 2024 | 14488 | 0.100 |
Why?
| | Diabetic Nephropathies | 2 | 2014 | 284 | 0.100 |
Why?
| | Capacity Building | 1 | 2012 | 59 | 0.100 |
Why?
| | Premenopause | 2 | 2003 | 121 | 0.100 |
Why?
| | Smoking | 6 | 2010 | 1499 | 0.100 |
Why?
| | Kidney | 2 | 2021 | 1375 | 0.090 |
Why?
| | Counseling | 1 | 2015 | 384 | 0.090 |
Why?
| | Clinical Protocols | 1 | 1993 | 254 | 0.090 |
Why?
| | Myocardial Revascularization | 1 | 2011 | 71 | 0.090 |
Why?
| | Health Promotion | 1 | 2017 | 717 | 0.090 |
Why?
| | Heart Ventricles | 1 | 2016 | 779 | 0.090 |
Why?
| | Linear Models | 2 | 2014 | 818 | 0.090 |
Why?
| | Research Report | 1 | 2011 | 76 | 0.090 |
Why?
| | Benchmarking | 1 | 2012 | 175 | 0.090 |
Why?
| | Comorbidity | 4 | 2021 | 1545 | 0.090 |
Why?
| | Sickness Impact Profile | 1 | 2011 | 55 | 0.090 |
Why?
| | Hemoglobins | 2 | 2017 | 339 | 0.090 |
Why?
| | Self Concept | 1 | 2012 | 242 | 0.090 |
Why?
| | Hyperemia | 1 | 2011 | 48 | 0.090 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2009 | 160 | 0.090 |
Why?
| | Consensus | 3 | 2019 | 612 | 0.090 |
Why?
| | Coronary Disease | 4 | 2004 | 385 | 0.080 |
Why?
| | Niacin | 1 | 2010 | 19 | 0.080 |
Why?
| | Young Adult | 6 | 2024 | 12403 | 0.080 |
Why?
| | Affect | 1 | 2012 | 286 | 0.080 |
Why?
| | Lovastatin | 1 | 2010 | 37 | 0.080 |
Why?
| | Atherosclerosis | 2 | 2011 | 402 | 0.080 |
Why?
| | Hypertrophy, Left Ventricular | 2 | 2009 | 126 | 0.080 |
Why?
| | C-Reactive Protein | 2 | 2009 | 400 | 0.080 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2002 | 440 | 0.080 |
Why?
| | Gonadal Steroid Hormones | 1 | 1990 | 130 | 0.080 |
Why?
| | Body Fat Distribution | 1 | 2009 | 49 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 527 | 0.080 |
Why?
| | Heart Function Tests | 1 | 2009 | 59 | 0.080 |
Why?
| | Hospitalization | 1 | 2018 | 2069 | 0.080 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2009 | 66 | 0.080 |
Why?
| | Aorta | 1 | 2011 | 411 | 0.080 |
Why?
| | Hyperinsulinism | 2 | 2010 | 119 | 0.080 |
Why?
| | Thinness | 1 | 2009 | 89 | 0.080 |
Why?
| | Heart Failure | 3 | 2018 | 2147 | 0.080 |
Why?
| | Psychometrics | 1 | 2012 | 684 | 0.080 |
Why?
| | Age Factors | 4 | 2021 | 3137 | 0.080 |
Why?
| | Fasting | 2 | 2005 | 266 | 0.080 |
Why?
| | Analysis of Variance | 4 | 2012 | 1285 | 0.080 |
Why?
| | Perfusion | 1 | 2009 | 197 | 0.070 |
Why?
| | Puberty | 1 | 2009 | 143 | 0.070 |
Why?
| | Cost-Benefit Analysis | 4 | 2014 | 567 | 0.070 |
Why?
| | Angina Pectoris | 1 | 2008 | 67 | 0.070 |
Why?
| | Mitochondria | 1 | 2014 | 875 | 0.070 |
Why?
| | Myoglobin | 1 | 2007 | 12 | 0.070 |
Why?
| | Aging | 1 | 2018 | 1774 | 0.070 |
Why?
| | Inflammation | 3 | 2009 | 2723 | 0.070 |
Why?
| | Leisure Activities | 2 | 2006 | 29 | 0.070 |
Why?
| | Awareness | 1 | 2008 | 99 | 0.070 |
Why?
| | Prospective Studies | 8 | 2019 | 7103 | 0.070 |
Why?
| | Prevalence | 3 | 2019 | 2559 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2008 | 1278 | 0.070 |
Why?
| | Dyspnea | 1 | 2008 | 239 | 0.060 |
Why?
| | Regression Analysis | 5 | 1998 | 993 | 0.060 |
Why?
| | Chronic Disease | 2 | 2023 | 1713 | 0.060 |
Why?
| | Neoplasms | 2 | 2010 | 2467 | 0.060 |
Why?
| | Glycation End Products, Advanced | 1 | 2006 | 76 | 0.060 |
Why?
| | Blood Viscosity | 2 | 1995 | 16 | 0.060 |
Why?
| | Lipids | 1 | 2009 | 624 | 0.060 |
Why?
| | Metformin | 2 | 2010 | 315 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2009 | 720 | 0.060 |
Why?
| | Pulmonary Circulation | 1 | 2007 | 430 | 0.060 |
Why?
| | Multicenter Studies as Topic | 2 | 2004 | 286 | 0.060 |
Why?
| | Glucose Clamp Technique | 1 | 2005 | 194 | 0.060 |
Why?
| | Hematocrit | 2 | 1995 | 93 | 0.060 |
Why?
| | Animals | 5 | 2018 | 35219 | 0.060 |
Why?
| | Sulfonic Acids | 1 | 2004 | 13 | 0.060 |
Why?
| | Guilt | 1 | 2024 | 12 | 0.060 |
Why?
| | Population Dynamics | 1 | 1985 | 136 | 0.060 |
Why?
| | Nutrition Surveys | 1 | 2006 | 260 | 0.060 |
Why?
| | Work-Life Balance | 1 | 2024 | 18 | 0.060 |
Why?
| | Estrogens | 2 | 2010 | 346 | 0.060 |
Why?
| | Cohort Studies | 3 | 2016 | 5408 | 0.060 |
Why?
| | Incidence | 3 | 2019 | 2638 | 0.060 |
Why?
| | Acetates | 1 | 2004 | 100 | 0.060 |
Why?
| | Health Maintenance Organizations | 1 | 2004 | 97 | 0.060 |
Why?
| | Dietary Carbohydrates | 1 | 2004 | 150 | 0.050 |
Why?
| | Body Weight | 2 | 2006 | 938 | 0.050 |
Why?
| | Biopsy | 3 | 2012 | 1087 | 0.050 |
Why?
| | Physicians, Women | 1 | 2024 | 70 | 0.050 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 90 | 0.050 |
Why?
| | Intracranial Arterial Diseases | 1 | 2002 | 8 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2004 | 312 | 0.050 |
Why?
| | Child | 5 | 2017 | 20853 | 0.050 |
Why?
| | Dietary Fats | 1 | 2004 | 301 | 0.050 |
Why?
| | Musculoskeletal Diseases | 1 | 2003 | 69 | 0.050 |
Why?
| | Glycolysis | 1 | 2024 | 309 | 0.050 |
Why?
| | Serum Globulins | 1 | 2002 | 5 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 297 | 0.050 |
Why?
| | Genetic Therapy | 1 | 2004 | 292 | 0.050 |
Why?
| | Prognosis | 2 | 2010 | 3791 | 0.050 |
Why?
| | Lung | 1 | 2015 | 3916 | 0.050 |
Why?
| | Ambulatory Care | 2 | 2014 | 504 | 0.050 |
Why?
| | Psychomotor Performance | 1 | 2004 | 312 | 0.050 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2002 | 84 | 0.050 |
Why?
| | Alcohol Drinking | 2 | 2010 | 759 | 0.050 |
Why?
| | Pelvis | 1 | 2002 | 103 | 0.050 |
Why?
| | Single-Blind Method | 2 | 2013 | 271 | 0.050 |
Why?
| | Adipose Tissue | 1 | 2005 | 590 | 0.050 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2001 | 85 | 0.050 |
Why?
| | Proteinuria | 1 | 2001 | 91 | 0.050 |
Why?
| | Diet | 2 | 2010 | 1212 | 0.050 |
Why?
| | Homocysteine | 1 | 2002 | 152 | 0.050 |
Why?
| | Patient Satisfaction | 2 | 2002 | 628 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 826 | 0.050 |
Why?
| | Physical Examination | 1 | 2002 | 235 | 0.050 |
Why?
| | Fibrinogen | 1 | 2002 | 164 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2002 | 169 | 0.040 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 262 | 0.040 |
Why?
| | Altitude | 1 | 1985 | 457 | 0.040 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2000 | 28 | 0.040 |
Why?
| | Multivariate Analysis | 3 | 2014 | 1500 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 198 | 0.040 |
Why?
| | Administration, Oral | 1 | 2003 | 783 | 0.040 |
Why?
| | Cholesterol, LDL | 2 | 2014 | 358 | 0.040 |
Why?
| | Myocardial Ischemia | 1 | 2002 | 250 | 0.040 |
Why?
| | Tissue Plasminogen Activator | 1 | 2002 | 221 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2004 | 740 | 0.040 |
Why?
| | Internal Medicine | 1 | 2002 | 246 | 0.040 |
Why?
| | Medroxyprogesterone Acetate | 2 | 1990 | 35 | 0.040 |
Why?
| | Specialties, Surgical | 1 | 2000 | 73 | 0.040 |
Why?
| | Organization and Administration | 1 | 2019 | 9 | 0.040 |
Why?
| | Pregnancy | 3 | 2020 | 6384 | 0.040 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 91 | 0.040 |
Why?
| | Femoral Artery | 2 | 2011 | 173 | 0.040 |
Why?
| | Rural Population | 2 | 1995 | 517 | 0.040 |
Why?
| | Sports Medicine | 2 | 2010 | 109 | 0.040 |
Why?
| | Asia | 1 | 2018 | 58 | 0.040 |
Why?
| | Risk Adjustment | 1 | 2019 | 79 | 0.040 |
Why?
| | Densitometry | 1 | 1998 | 34 | 0.040 |
Why?
| | Apoptosis | 1 | 2007 | 2501 | 0.040 |
Why?
| | Social Stigma | 1 | 2020 | 117 | 0.040 |
Why?
| | Lactic Acid | 2 | 1998 | 302 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2019 | 125 | 0.040 |
Why?
| | Hypercapnia | 2 | 1989 | 49 | 0.040 |
Why?
| | Public Health | 1 | 2023 | 482 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2020 | 240 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 336 | 0.040 |
Why?
| | Walking Speed | 1 | 2018 | 44 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2019 | 218 | 0.040 |
Why?
| | Cell Respiration | 1 | 2018 | 98 | 0.040 |
Why?
| | Autonomic Nervous System | 1 | 1998 | 75 | 0.040 |
Why?
| | Depression | 1 | 2007 | 1302 | 0.040 |
Why?
| | Walk Test | 1 | 2018 | 70 | 0.040 |
Why?
| | Hand Strength | 1 | 2018 | 113 | 0.040 |
Why?
| | Smoking Cessation | 1 | 2002 | 407 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 248 | 0.040 |
Why?
| | Neural Conduction | 2 | 1995 | 83 | 0.040 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2017 | 62 | 0.040 |
Why?
| | Drug Therapy, Combination | 2 | 2010 | 1037 | 0.040 |
Why?
| | Capillary Resistance | 1 | 2017 | 5 | 0.040 |
Why?
| | Acute Disease | 1 | 2020 | 977 | 0.040 |
Why?
| | Career Choice | 1 | 2019 | 207 | 0.040 |
Why?
| | Oxyhemoglobins | 1 | 2017 | 21 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2013 | 3067 | 0.030 |
Why?
| | Caloric Restriction | 1 | 2018 | 109 | 0.030 |
Why?
| | Family Practice | 1 | 2001 | 456 | 0.030 |
Why?
| | Weight Reduction Programs | 1 | 2018 | 111 | 0.030 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2017 | 48 | 0.030 |
Why?
| | Canada | 1 | 2018 | 347 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 1834 | 0.030 |
Why?
| | Forecasting | 2 | 2000 | 358 | 0.030 |
Why?
| | Heart | 1 | 2020 | 637 | 0.030 |
Why?
| | Bicycling | 1 | 2017 | 116 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 588 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2017 | 370 | 0.030 |
Why?
| | Stroke Volume | 1 | 2018 | 590 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 340 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 334 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 1995 | 40 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2016 | 248 | 0.030 |
Why?
| | Energy Intake | 3 | 2006 | 459 | 0.030 |
Why?
| | Risk | 1 | 2017 | 854 | 0.030 |
Why?
| | Electrophysiology | 1 | 1995 | 210 | 0.030 |
Why?
| | Cystatin C | 1 | 2014 | 65 | 0.030 |
Why?
| | Vascular Patency | 1 | 2014 | 102 | 0.030 |
Why?
| | Models, Economic | 1 | 2014 | 53 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2014 | 106 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2019 | 737 | 0.030 |
Why?
| | Life Expectancy | 1 | 2014 | 61 | 0.030 |
Why?
| | Phosphorus | 1 | 2014 | 93 | 0.030 |
Why?
| | Databases, Factual | 2 | 2011 | 1269 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2016 | 465 | 0.030 |
Why?
| | Hospital Costs | 1 | 2014 | 114 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 2014 | 228 | 0.030 |
Why?
| | Drug Costs | 1 | 2014 | 100 | 0.030 |
Why?
| | Health Behavior | 1 | 2019 | 741 | 0.030 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2014 | 141 | 0.030 |
Why?
| | Health Education | 1 | 2016 | 333 | 0.030 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2014 | 203 | 0.030 |
Why?
| | Collateral Circulation | 2 | 2003 | 18 | 0.030 |
Why?
| | Carotid Stenosis | 1 | 2014 | 84 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 763 | 0.030 |
Why?
| | Internship and Residency | 1 | 2002 | 1049 | 0.030 |
Why?
| | Administrative Personnel | 1 | 2012 | 29 | 0.030 |
Why?
| | Creatinine | 1 | 2014 | 490 | 0.030 |
Why?
| | Blood Vessel Prosthesis | 1 | 2013 | 124 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 715 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2013 | 306 | 0.020 |
Why?
| | Waist Circumference | 1 | 2012 | 138 | 0.020 |
Why?
| | Treatment Failure | 1 | 2013 | 339 | 0.020 |
Why?
| | Health Planning | 1 | 1992 | 47 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1477 | 0.020 |
Why?
| | North Carolina | 1 | 2012 | 99 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 70 | 0.020 |
Why?
| | Behavior Therapy | 1 | 2014 | 238 | 0.020 |
Why?
| | Muscle Strength | 1 | 2014 | 303 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 1992 | 90 | 0.020 |
Why?
| | Muscle Contraction | 1 | 2014 | 422 | 0.020 |
Why?
| | Popliteal Artery | 1 | 2011 | 58 | 0.020 |
Why?
| | Estrone | 1 | 1991 | 36 | 0.020 |
Why?
| | Radioimmunoassay | 1 | 1991 | 175 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 857 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2014 | 707 | 0.020 |
Why?
| | Follicular Phase | 1 | 1990 | 38 | 0.020 |
Why?
| | C-Peptide | 1 | 1991 | 163 | 0.020 |
Why?
| | Metabolism | 1 | 1990 | 38 | 0.020 |
Why?
| | Luteal Phase | 1 | 1990 | 44 | 0.020 |
Why?
| | Incretins | 1 | 2010 | 18 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2010 | 65 | 0.020 |
Why?
| | Actigraphy | 1 | 2010 | 98 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 511 | 0.020 |
Why?
| | Receptor, Insulin | 1 | 2010 | 99 | 0.020 |
Why?
| | Acetylcarnitine | 1 | 1989 | 4 | 0.020 |
Why?
| | Health Services Research | 1 | 2012 | 391 | 0.020 |
Why?
| | Progesterone | 1 | 1991 | 243 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 832 | 0.020 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2015 | 466 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1093 | 0.020 |
Why?
| | Risk Assessment | 2 | 2009 | 3234 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2010 | 173 | 0.020 |
Why?
| | Respiration Disorders | 1 | 1989 | 72 | 0.020 |
Why?
| | Energy Metabolism | 3 | 2006 | 869 | 0.020 |
Why?
| | Partial Pressure | 1 | 1988 | 29 | 0.020 |
Why?
| | Estradiol | 1 | 1991 | 492 | 0.020 |
Why?
| | Tidal Volume | 1 | 1988 | 84 | 0.020 |
Why?
| | Ankle Joint | 1 | 2008 | 104 | 0.020 |
Why?
| | Drug Interactions | 1 | 1989 | 390 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2009 | 209 | 0.020 |
Why?
| | Fluoroquinolones | 1 | 2007 | 45 | 0.020 |
Why?
| | Testosterone | 1 | 2010 | 371 | 0.020 |
Why?
| | Pain | 1 | 1993 | 770 | 0.020 |
Why?
| | Caspase 3 | 1 | 2007 | 244 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2010 | 327 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2014 | 2720 | 0.020 |
Why?
| | Models, Cardiovascular | 1 | 2007 | 191 | 0.020 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2006 | 31 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2007 | 811 | 0.020 |
Why?
| | Income | 1 | 2007 | 189 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 1989 | 252 | 0.020 |
Why?
| | Carbon Dioxide | 1 | 1988 | 258 | 0.020 |
Why?
| | Sterol O-Acyltransferase | 1 | 2004 | 5 | 0.010 |
Why?
| | Receptors, Immunologic | 1 | 2006 | 216 | 0.010 |
Why?
| | Acetamides | 1 | 2004 | 36 | 0.010 |
Why?
| | Case Management | 1 | 2004 | 64 | 0.010 |
Why?
| | Age Distribution | 1 | 2004 | 372 | 0.010 |
Why?
| | Cell Adhesion Molecules | 1 | 2004 | 173 | 0.010 |
Why?
| | Gene Transfer Techniques | 1 | 2004 | 163 | 0.010 |
Why?
| | Calcium-Binding Proteins | 1 | 2004 | 210 | 0.010 |
Why?
| | Cognition Disorders | 1 | 2007 | 503 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3390 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 375 | 0.010 |
Why?
| | Cytokines | 1 | 2010 | 2011 | 0.010 |
Why?
| | Endpoint Determination | 1 | 2001 | 76 | 0.010 |
Why?
| | Lactates | 2 | 1992 | 84 | 0.010 |
Why?
| | Ultrasonography, Doppler | 1 | 2001 | 118 | 0.010 |
Why?
| | Sulfonamides | 1 | 2004 | 496 | 0.010 |
Why?
| | Algorithms | 1 | 2008 | 1618 | 0.010 |
Why?
| | Wound Healing | 1 | 2003 | 303 | 0.010 |
Why?
| | Attitude | 1 | 2002 | 258 | 0.010 |
Why?
| | World Health Organization | 1 | 2000 | 110 | 0.010 |
Why?
| | Artificial Limbs | 1 | 2003 | 173 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 2000 | 201 | 0.010 |
Why?
| | Logistic Models | 1 | 2004 | 1983 | 0.010 |
Why?
| | Models, Biological | 1 | 2006 | 1718 | 0.010 |
Why?
| | Indians, North American | 1 | 2004 | 600 | 0.010 |
Why?
| | Interpersonal Relations | 1 | 2002 | 391 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2002 | 1214 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2000 | 543 | 0.010 |
Why?
| | Diabetic Neuropathies | 1 | 1998 | 96 | 0.010 |
Why?
| | Diabetic Retinopathy | 1 | 1998 | 172 | 0.010 |
Why?
| | Muscle Fibers, Skeletal | 1 | 1996 | 187 | 0.010 |
Why?
| | Rehabilitation | 1 | 1992 | 16 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 1991 | 205 | 0.010 |
Why?
| | Electromyography | 1 | 1992 | 381 | 0.010 |
Why?
| | Hydroxybutyrates | 1 | 1989 | 14 | 0.010 |
Why?
| | 3-Hydroxybutyric Acid | 1 | 1989 | 15 | 0.010 |
Why?
| | Blood Gas Analysis | 1 | 1989 | 71 | 0.010 |
Why?
| | Nervous System Diseases | 1 | 1992 | 252 | 0.000 |
Why?
| | Ultrasonics | 1 | 1989 | 49 | 0.000 |
Why?
| | Action Potentials | 1 | 1992 | 485 | 0.000 |
Why?
| | Sleep Apnea Syndromes | 1 | 1989 | 80 | 0.000 |
Why?
| | Drug Combinations | 1 | 1989 | 327 | 0.000 |
Why?
| | Mice | 1 | 1989 | 16861 | 0.000 |
Why?
|
|
Regensteiner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|